-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] In order to better survive and develop in the competition, many pharmaceutical companies are currently focusing on their main business and divesting some businesses and produc.
Among them, it is worth noting that some companies are accelerating the "slimming" by frequently selling produc.
Recently, Sanofi and Neuraxpharm reached an agreement to sell 17 drugs to Neuraxpharm for an undisclosed amou.
The drugs are understood to include two product portfolios for central nervous system (CNS) disorders, pain and vascular disorde.
The 17 Sanofi drugs collectively make up 38 brands, and together this suite of products is being sold in more than 50 countries around the wor.
In fact, in recent years, Sanofi has been actively trying to "slim down" by selling products in order to practice the "play to win" (winning strategy) proposed in 201It is reported that this is a plan from 2020 to 2025, focusing on key research and development areas such as immune inflammation, rare diseases, tumors, and vaccin.
Specifically, in November 2019, Sanofi revealed plans to spin off its consumer health busine.
On February 24, 2020, Sanofi announced the merger of its six API manufacturing sites in Europe to create an independent API compa.
In the same year, Sanofi also agreed to sell a majority stake in US drugmaker Regeneron for $13 billion (HK$104 billio.
On April 26, 2021, it was reported that Sanofi India is in advanced talks to sell part of its OTC busine.
The Indian arm of the French pharma giant is reportedly considering a sale of its nutrition and vitamins business for an estimated price of Rs 600 cro.
In June, Sanofi sold another 16 consumer healthcare product assets to Germany's Stada Arzneimitt.
The product portfolio includes cold and flu medicines, skincare and food supplement bran.
Since the beginning of this year, Sanofi has still made frequent moves in terms of "slim dow.
In April, Sanofi announced that the French securities market regulator AMF has approved the listing prospectus of its API company EUROA.
Once approved by the general meeting of shareholders, it is expected to be split and listed on Euronext Paris on May
In June, Sanofi sold its longtime partner Regeneron's exclusive worldwide rights to the cancer drug Libtayo for $900 milli.
Notably, in addition to product sales and spin-offs, Sanofi is "cutting costs" through layof.
It is reported that shortly after announcing the change of LOGO at the beginning of the year, Sanofi Chief Financial Officer Jean Baptiste stated in the quarterly investor conference call that the company intends to continue to “slim down” and expects to lay off 6,000 jobs worldwide throughout the ye.
It is understood that Sanofi has been promoting layoffs in recent yea.
In late January 2018, due to the poor sales of insulin Lantus, Sanofi announced that it would lay off 400 employees in the diabetes and cardiovascular sales team in the United States; on June 20, 2019, Sanofi announced that it would lay off 466 employees in France and Germa.
After the reorganization, the cardiovascular research project was terminated, the scope of diabetes work was reduced, and the focus of research and development was shifted to the fields of oncology, immunology, and rare diseas.
In 2020, Sanofi announced that it plans to cut 1,700 jobs in Europe, of which about 1,000 jobs will be cut in France in the next three years, that is, an average of about 350 people per ye.
Due to the pressure of drug price cuts and patent expiry, the profit growth of the entire pharmaceutical industry is sluggish; in addition, many multinational pharmaceutical companies have frequently expanded, and the problem of excessive investment has emerged; at present, through timely adjustment of layout, spin-offs, mergers and acquisitions and other methods The transition has become the main strategic adjustment direction of pharmaceutical compani.
In fact, in addition to Sanofi, in recent years, a large number of pharmaceutical companies such as Merck, GSK, e.
have also started business splits and "slimming" pla.
In the future, with the increasingly fierce competition in the pharmaceutical industry, in order to improve product lines and expand core areas, more and more pharmaceutical companies are expected to choose to “slim dow.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Among them, it is worth noting that some companies are accelerating the "slimming" by frequently selling produc.
Recently, Sanofi and Neuraxpharm reached an agreement to sell 17 drugs to Neuraxpharm for an undisclosed amou.
The drugs are understood to include two product portfolios for central nervous system (CNS) disorders, pain and vascular disorde.
The 17 Sanofi drugs collectively make up 38 brands, and together this suite of products is being sold in more than 50 countries around the wor.
In fact, in recent years, Sanofi has been actively trying to "slim down" by selling products in order to practice the "play to win" (winning strategy) proposed in 201It is reported that this is a plan from 2020 to 2025, focusing on key research and development areas such as immune inflammation, rare diseases, tumors, and vaccin.
Specifically, in November 2019, Sanofi revealed plans to spin off its consumer health busine.
On February 24, 2020, Sanofi announced the merger of its six API manufacturing sites in Europe to create an independent API compa.
In the same year, Sanofi also agreed to sell a majority stake in US drugmaker Regeneron for $13 billion (HK$104 billio.
On April 26, 2021, it was reported that Sanofi India is in advanced talks to sell part of its OTC busine.
The Indian arm of the French pharma giant is reportedly considering a sale of its nutrition and vitamins business for an estimated price of Rs 600 cro.
In June, Sanofi sold another 16 consumer healthcare product assets to Germany's Stada Arzneimitt.
The product portfolio includes cold and flu medicines, skincare and food supplement bran.
Since the beginning of this year, Sanofi has still made frequent moves in terms of "slim dow.
In April, Sanofi announced that the French securities market regulator AMF has approved the listing prospectus of its API company EUROA.
Once approved by the general meeting of shareholders, it is expected to be split and listed on Euronext Paris on May
In June, Sanofi sold its longtime partner Regeneron's exclusive worldwide rights to the cancer drug Libtayo for $900 milli.
Notably, in addition to product sales and spin-offs, Sanofi is "cutting costs" through layof.
It is reported that shortly after announcing the change of LOGO at the beginning of the year, Sanofi Chief Financial Officer Jean Baptiste stated in the quarterly investor conference call that the company intends to continue to “slim down” and expects to lay off 6,000 jobs worldwide throughout the ye.
It is understood that Sanofi has been promoting layoffs in recent yea.
In late January 2018, due to the poor sales of insulin Lantus, Sanofi announced that it would lay off 400 employees in the diabetes and cardiovascular sales team in the United States; on June 20, 2019, Sanofi announced that it would lay off 466 employees in France and Germa.
After the reorganization, the cardiovascular research project was terminated, the scope of diabetes work was reduced, and the focus of research and development was shifted to the fields of oncology, immunology, and rare diseas.
In 2020, Sanofi announced that it plans to cut 1,700 jobs in Europe, of which about 1,000 jobs will be cut in France in the next three years, that is, an average of about 350 people per ye.
Due to the pressure of drug price cuts and patent expiry, the profit growth of the entire pharmaceutical industry is sluggish; in addition, many multinational pharmaceutical companies have frequently expanded, and the problem of excessive investment has emerged; at present, through timely adjustment of layout, spin-offs, mergers and acquisitions and other methods The transition has become the main strategic adjustment direction of pharmaceutical compani.
In fact, in addition to Sanofi, in recent years, a large number of pharmaceutical companies such as Merck, GSK, e.
have also started business splits and "slimming" pla.
In the future, with the increasingly fierce competition in the pharmaceutical industry, in order to improve product lines and expand core areas, more and more pharmaceutical companies are expected to choose to “slim dow.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
